Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BridgeBio Pharma's Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-571.96 Mil. Therefore, BridgeBio Pharma's EV-to-EBIT ratio for today is -10.33.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BridgeBio Pharma's Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-565.47 Mil. Therefore, BridgeBio Pharma's EV-to-EBITDA ratio for today is -10.45.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BridgeBio Pharma's Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $9.30 Mil. Therefore, BridgeBio Pharma's EV-to-Revenue ratio for today is 634.96.
BridgeBio Pharma Enterprise Value Historical Data
The historical data trend for BridgeBio Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BridgeBio Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Enterprise Value Distribution
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Enterprise Value falls into.
BridgeBio Pharma Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
BridgeBio Pharma's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (NAS:BBIO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
BridgeBio Pharma's current Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-571.96 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
BridgeBio Pharma's current Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-565.47 Mil.
BridgeBio Pharma's current Enterprise Value is $5,907.04 Mil.
BridgeBio Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma Enterprise Value Related Terms
Thank you for viewing the detailed overview of BridgeBio Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
BridgeBio Pharma (BridgeBio Pharma) Business Description
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your 